About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Test Helps Treat Severe Ovarian Cancer

by Ramya Rachamanti on June 18, 2020 at 1:33 PM
New Test Helps Treat Severe Ovarian Cancer

New test could guide and improve treatment options for women diagnosed with ovarian cancer. The development and validation of the test are outlined in a new study, published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

The study--led by researchers at UBC's faculty of medicine, University of New South Wales, Huntsman Cancer Institute, Peter MacCallum Cancer Centre and Mayo Clinic--is one of the largest ovarian cancer investigations to date, involving data compiled by more than 50 research institutes and involving more than 3,800 ovarian cancer patients worldwide.

Advertisement


"With this new test, we'll be able to give researchers, clinicians and patients more insight into the disease, which could pave the way for more targeted treatment down the road," says the study's senior author, Dr. Michael Anglesio, a molecular biologist, assistant professor in UBC's department of obstetrics and gynaecology, investigator at the Vancouver Coastal Health Research Institute (VCHRI) and scientist at OVCARE, B.C.'s multidisciplinary gynecological cancer research team.

The new test, known as PrOTYPE (Predictor of high-grade serous Ovarian carcinoma molecular subTYPE), is specifically designed to analyze and classify high-grade serous ovarian cancer, the most common and lethal form of ovarian cancer. Principal investigators validated the test in laboratories at BC Cancer and Vancouver General Hospital.
Advertisement

Using PrOTYPE, researchers and clinicians alike will be able to further classify an individual patient's tumour into one of four known molecular subtypes, each with its distinct biological features believed to respond differently to treatment options.

"Right now, high-grade serous ovarian cancer patients are all treated the same, but by knowing what subtype their tumour falls into, we can begin to explore how certain treatments may prove more beneficial for individual patients," says the study's lead author Dr. Aline Talhouk, a translational data scientist, assistant professor in UBC's department of obstetrics and gynaecology, VCHRI investigator and OVCARE scientist.

Prior to the development of PrOTYPE, subtyping tests using gene expression analysis for high-grade serous ovarian cancer relied on the aggregation of large patient cohorts and the examination of all of the genes in the genome at once -- a situation that made them impractical for use in clinical settings, says Anglesio.

"Doctors will never see a few hundred patients walk through their clinic door at one time. It's just not the reality," says Anglesio.

With PrOTYPE, which was designed for clinical use, a small amount of information--55 informative genes from a small tissue sample--can quickly determine the tumour subtype with more than 95 per cent accuracy. The researchers also developed a corresponding web tool, enabling clinicians to print out a report that can be added to a patient's records.

"We've developed a push-button solution. All that's needed is the tumour from the patient in question and a common reference to compare the data to. Before this test, no one could do that," says Anglesio. "We now have a robust way of figuring out which of the four subtypes a patient fits into."

The researchers see great potential for the test to one day guide patient care. The test is already being used in ongoing clinical trials investigating whether certain subtypes are more sensitive to particular treatments among women with recurrent high-grade serous ovarian cancer.

"This test has opened up new opportunities and treatment avenues to explore. It will be important to re-evaluate treatment options and test new targets for therapeutics in light of this new ability," says Talhouk.



Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Cancer News

Link Between Poor Oral Health and Head & Neck Cancer Survival Uncovered
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
Painless Lumps in the Body May Signal Lymphatic Cancer Risk
The presence of painless swelling in the lymph nodes could potentially indicate lymphatic cancer, say experts.
Non-clinical Genetic Testing May Lead to Needless Breast Surgery
Women tested at high risk for breast cancer using non-clinical genetic tests overlooking family history may decide to undergo unnecessary breast surgery.
Promising Drug Combination Offers Hope for Liver Cancer Patients
Atezolizumab-bevacizumab drug combination can yield positive outcomes in terms of extended survival and the elimination of liver cancer.
Most Esophageal Reflux Patients Face No Elevated Cancer Risk
Reflux disease manifests as acid regurgitation and heartburn and is a known risk factor for esophageal cancer.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

New Test Helps Treat Severe Ovarian Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests